FHTX (Foghorn Therapeutics) Institutional Ownership : 76.50% (As of Apr. 18, 2025)

View and export this data going back to 2020. Start your Free Trial

What is Foghorn Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Foghorn Therapeutics's institutional ownership is 76.50%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Foghorn Therapeutics's Insider Ownership is 1.98%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Foghorn Therapeutics's Float Percentage Of Total Shares Outstanding is 63.69%.

Foghorn Therapeutics Institutional Ownership Historical Data

The historical data trend for Foghorn Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Foghorn Therapeutics Institutional Ownership Chart

Foghorn Therapeutics Historical Data

The historical data trend for Foghorn Therapeutics can be seen below:

	2024-06-30	2024-07-31	2024-08-31	2024-09-30	2024-10-31	2024-11-30	2024-12-31	2025-01-31	2025-02-28	2025-03-31
Institutional Ownership	19.19	19.89	21.09	21.34	21.02	21.10	20.73	20.38	20.47	20.50

Foghorn Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Foghorn Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Foghorn Therapeutics Inc (NAS:FHTX) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

500 Technology Square, Suite 700, Cambridge, MA, USA, 02139

Website

https://www.foghorntx.com

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Executives

Carlos Costa	officer: Chief People Officer	C/O FOGHORN THERAPEUTICS INC., 500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE MA 02139
Steven F. Bellon	officer: See Remarks	500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE MA 02139
Fanny Cavalie	officer: Chief Strategy/Bus Ops Officer	C/O FOGHORN THERAPEUTICS INC., 500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE MA 02139
Alfonso Quintas Cardama	officer: Chief Medical Officer	C/O TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142
Samuel Agresta	officer: Chief Medical Officer	784 MEMORIAL DR., CAMBRIDGE MA 02139
Lynch Thomas J. Jr.	director	800 HOWARD AVENUE, YALE PHYSICIANS BUILDING, 2ND FLOOR, NEW HAVEN CT 06519
B Lynne Parshall	director	2855 GAZELLE COURT, CARLSBAD CA 92010
Ian F Smith	director	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Michael Lacascia	officer: Chief Legal Officer	500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE MA 02139
Carl Decicco	officer: Chief Scientific Officer	100 BINNEY STREET, SUITE 610, CAMBRIDGE MA 02142
Flagship Ventures Opportunities Fund I General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Abu Dhabi Investment Authority	10 percent owner	211 CORNICHE STREET, PO BOX 3600, ABU DHABI C0 0000
Platinum International Investment Holding Rsc Ltd	10 percent owner	26TH FLOOR, AL KHATEM TOWER, ADGM SQUARE, PO BOX 25642, AL MARYAH ISLAND, ABU DHABI C0 NA
Adam Koppel	director	C/O BROOKSIDE CAPITAL, LLC, JOHN HANCOCK TOWER, 200 CLARENDON ST, BOSTON MA 02116
Jose Baselga	director	780 MEMORIAL DRIVE, CAMBRIDGE MA 02139